Last reviewed · How we verify
Empagliflozin Pill
Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.
Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.
At a glance
| Generic name | Empagliflozin Pill |
|---|---|
| Also known as | Jardiance, Empagliflozin |
| Sponsor | Centro Universitario de Ciencias de la Salud, Mexico |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, empagliflozin prevents glucose reabsorption, allowing excess glucose to be excreted in the urine. This mechanism lowers blood glucose independently of insulin secretion and also provides cardiovascular and renal protective benefits through osmotic diuresis and reduced intraglomerular pressure.
Approved indications
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Hypotension
- Diabetic ketoacidosis
Key clinical trials
- Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients (PHASE4)
- DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis (PHASE4)
- Polypill Strategy for Heart Failure With Reduced Ejection Fraction (PHASE2)
- Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease (PHASE4)
- Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure (EARLY_PHASE1)
- SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.
- Glycemic Control with Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination (PHASE4)
- Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Empagliflozin Pill CI brief — competitive landscape report
- Empagliflozin Pill updates RSS · CI watch RSS
- Centro Universitario de Ciencias de la Salud, Mexico portfolio CI